JP6606213B2 - Health promoting composition that generates photons and ions - Google Patents
Health promoting composition that generates photons and ions Download PDFInfo
- Publication number
- JP6606213B2 JP6606213B2 JP2018061842A JP2018061842A JP6606213B2 JP 6606213 B2 JP6606213 B2 JP 6606213B2 JP 2018061842 A JP2018061842 A JP 2018061842A JP 2018061842 A JP2018061842 A JP 2018061842A JP 6606213 B2 JP6606213 B2 JP 6606213B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- weight
- fiber
- component
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 109
- 150000002500 ions Chemical class 0.000 title claims description 18
- 230000036541 health Effects 0.000 title claims description 13
- 230000001737 promoting effect Effects 0.000 title description 5
- 239000000835 fiber Substances 0.000 claims description 72
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 44
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 30
- 238000002156 mixing Methods 0.000 claims description 24
- 229910052697 platinum Inorganic materials 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 19
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 18
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 16
- 239000000377 silicon dioxide Substances 0.000 claims description 15
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 13
- 229910052709 silver Inorganic materials 0.000 claims description 10
- 239000004332 silver Substances 0.000 claims description 10
- 229910001597 celsian Inorganic materials 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 8
- 150000003058 platinum compounds Chemical class 0.000 claims description 8
- 150000002344 gold compounds Chemical class 0.000 claims description 7
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052737 gold Inorganic materials 0.000 claims description 6
- 239000010931 gold Substances 0.000 claims description 6
- 150000002504 iridium compounds Chemical class 0.000 claims description 5
- 150000002941 palladium compounds Chemical class 0.000 claims description 5
- 150000003284 rhodium compounds Chemical class 0.000 claims description 5
- 229910052741 iridium Inorganic materials 0.000 claims description 4
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- 229910052703 rhodium Inorganic materials 0.000 claims description 4
- 239000010948 rhodium Substances 0.000 claims description 4
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 4
- 229940100890 silver compound Drugs 0.000 claims description 4
- 150000003379 silver compounds Chemical class 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 239000004744 fabric Substances 0.000 description 27
- 238000000034 method Methods 0.000 description 18
- -1 nitrate ions Chemical class 0.000 description 18
- 229920000728 polyester Polymers 0.000 description 17
- 229920000742 Cotton Polymers 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000002245 particle Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 239000000843 powder Substances 0.000 description 11
- 239000004594 Masterbatch (MB) Substances 0.000 description 10
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 10
- 239000000084 colloidal system Substances 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920002635 polyurethane Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 238000009987 spinning Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- 229910052581 Si3N4 Inorganic materials 0.000 description 3
- 229910004298 SiO 2 Inorganic materials 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 2
- 230000035584 blastogenesis Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000005976 liver dysfunction Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 239000005033 polyvinylidene chloride Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000790 scattering method Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 229920005992 thermoplastic resin Polymers 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RNFJDJUURJAICM-UHFFFAOYSA-N 2,2,4,4,6,6-hexaphenoxy-1,3,5-triaza-2$l^{5},4$l^{5},6$l^{5}-triphosphacyclohexa-1,3,5-triene Chemical compound N=1P(OC=2C=CC=CC=2)(OC=2C=CC=CC=2)=NP(OC=2C=CC=CC=2)(OC=2C=CC=CC=2)=NP=1(OC=1C=CC=CC=1)OC1=CC=CC=C1 RNFJDJUURJAICM-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229910010413 TiO 2 Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229920002978 Vinylon Polymers 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000000578 dry spinning Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000212 effect on lymphocytes Effects 0.000 description 1
- 230000001210 effect on neutrophils Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000003063 flame retardant Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002074 melt spinning Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002321 radial artery Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- CMWCOKOTCLFJOP-UHFFFAOYSA-N titanium(3+) Chemical compound [Ti+3] CMWCOKOTCLFJOP-UHFFFAOYSA-N 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 230000002883 vasorelaxation effect Effects 0.000 description 1
- 238000002166 wet spinning Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Landscapes
- Artificial Filaments (AREA)
Description
本発明は、健康増進に役立つ白金含有組成物に関する。 The present invention relates to a platinum-containing composition useful for promoting health.
白金を含む組成物は、遠赤外線を発生することが広く知られている。遠赤外線は、放射・輻射波長が数〜約４００μｍ領域の電磁波であって、加熱効果、乾燥効果に優れる。このため、遠赤外線放射体としてのセラミックスは、表面を過剰に加熱することなく内部まで均一に加熱できることから高品質の食品加工分野にも活用されてきた。また、遠赤外線放射材を繊維に練り込み又は表面に塗布した、遠赤外線効果を有する繊維は、寝具、洋服、下着等に幅広く用いられている。 It is widely known that a composition containing platinum generates far infrared rays. Far-infrared radiation is an electromagnetic wave having a radiation / radiation wavelength range of several to about 400 μm, and is excellent in heating effect and drying effect. For this reason, ceramics as far-infrared radiators have been utilized in the field of high-quality food processing because they can be heated uniformly to the inside without excessively heating the surface. Further, a fiber having a far-infrared effect, in which a far-infrared emitting material is kneaded into a fiber or applied to a surface, is widely used for bedding, clothes, underwear and the like.
例えば、特開昭６２−１８４０８８号公報には、アルミナとシリカとプラチナとを含む遠赤外線放射用の粉末が食品類の日持ちや食味の向上に効果を有することが記載されている。 For example, JP-A-62-184088 describes that far-infrared radiation powder containing alumina, silica, and platinum is effective in improving the shelf life and taste of foods.
特開平３−１９０９９０号公報には、アルミナとチタンとプラチナとを含む赤外線微弱エネルギー放射用の粉末が食品類の日持ちに効果を有するとともに、この粉末を含む合成繊維が血行を促進させ、温熱効果を有し、冷え性や関節痛の症状に効果があることが記載されている。 Japanese Patent Laid-Open No. 3-190990 discloses that a powder for infrared weak energy radiation containing alumina, titanium, and platinum has an effect on shelf life of foods, and a synthetic fiber containing this powder promotes blood circulation, and a thermal effect. It is described that it has an effect on coldness and symptoms of joint pain.
また、特開平３−２４１０２５号公報及び特開平４−７３２２６号公報には、アルミナとシリカとプラチナとからなる遠赤外線放射用粉末をナイロン又はポリエステルに混合して得た糸から製造した織物が生体に対して極めて良好な保温性を奏することが記載されている。 Further, in Japanese Patent Laid-Open Nos. 3-241025 and 4-73226, a fabric manufactured from yarn obtained by mixing far infrared radiation powder composed of alumina, silica and platinum into nylon or polyester is used as a living body. In contrast, it describes that it exhibits extremely good heat retention.
その後、白金を含む組成物であって、遠赤外線に加え、さらにフォトン（光子）及びマイナスイオンを発生する組成物が報告されている。
例えば、特許文献５には、アルミナと、シリカと、酸化チタンと、白金と、銀とを含む組成物が、遠赤外線及びフォトンを発生することが確認され、該組成物は、抗菌性・殺菌性に優れること、該組成物を繊維に混入した繊維製品は、除電性があることが記載されている。
また、特許文献６には、アルミナと、シリカと、酸化チタンと、白金と、銀とを含む組成物が、マイナスイオンを発生し、抗菌性を奏されるとともに、該組成物を含む繊維を使用した衣服又は寝具を使用することにより抗血栓性が奏されることが記載されている。
Thereafter, a composition containing platinum, which further generates photons (photons) and negative ions in addition to far infrared rays, has been reported.
For example, Patent Document 5 confirms that a composition containing alumina, silica, titanium oxide, platinum, and silver generates far-infrared rays and photons. It is described that the fiber product in which the composition is excellent and the fiber product in which the composition is mixed has a charge eliminating property.
Further, in Patent Document 6, a composition containing alumina, silica, titanium oxide, platinum, and silver generates negative ions, exhibits antibacterial properties, and includes fibers containing the composition. It is described that antithrombogenicity is achieved by using the used clothes or bedding.
しかしながら、特許文献６に記載された組成物が、どのような理由により抗血栓性が奏されるのかは解明されていなかった。特許文献６には、該組成物を含む繊維を使用した衣服又は寝具を使用すると、血液中の硝酸イオンの濃度が上がることが記載されている。硝酸イオンは、体内でＮＯが酸化されたものと考えられるが、このＮＯについては、体内で少量生じると、血管弛緩作用があることが知られている。 However, it has not been elucidated why the composition described in Patent Document 6 exhibits antithrombogenicity. Patent Document 6 describes that the use of clothes or bedding using fibers containing the composition increases the concentration of nitrate ions in blood. Nitrate ions are thought to have been NO oxidized in the body, but it is known that this NO has a vasorelaxing effect when produced in a small amount in the body.
したがって、この血管弛緩作用により特許文献６に記載された組成物は、さらにさまざまな健康増進効果があると考えられた。また、特許文献５および６に記載された組成物は、フォトン（光子）及びイオンを発生することから、その観点からもさらなる健康への影響を検証する必要があった。また、組成物の内容についても、健康増進効果を高めるさらなる成分につき、検討する必要があった。 Therefore, it was considered that the composition described in Patent Document 6 had various health promoting effects due to this vasorelaxant action. Further, since the compositions described in Patent Documents 5 and 6 generate photons (photons) and ions, it is necessary to verify further health effects from that viewpoint. Further, regarding the content of the composition, it was necessary to examine further components that enhance the health promotion effect.
本発明は、フォトン及びイオンを発生する組成物を健康増進に役立てることを目的とする。 An object of this invention is to make the composition which generate | occur | produce a photon and ion useful for health promotion.
本発明は、例えば以下の［１］〜［８］が挙げられる。
［１］（ｉ）アルミナと、（ｉｉ）シリカ及び酸化チタンからなる群から選択される少なくとも１種と、（ｉｉｉ）白金、白金化合物、パラジウム、パラジウム化合物、イリジウム、イリジウム化合物、ロジウム及びロジウム化合物からからなる群から選択される少なくとも１種と、（ｉｖ）セルシアンと、（ｖ）ステアタイトとを含むフォトン及びイオンを発生する健康増進組成物。
［２］更に、（ｖｉ）銀、銀化合物、金及び金化合物からなる群から選択される少なくとも１種を含む、［１］に記載の組成物。
［３］組成物１００重量部中、成分（ｉｉｉ）を０．００１５〜０．０３０重量部含む、［１］又は［２］に記載の組成物。
［４］組成物１００重量部中、成分（ｖｉ）を１．５〜３０重量部含む、［２］に記載の組成物。
［５］成分（ｉｉｉ）が、白金又は白金化合物である［１］〜［３］のいずれかに記載の組成物。
［６］［１］〜［５］のいずれかに記載の組成物を含む繊維。
［７］［１］〜［５］のいずれかに記載の組成物を含むフィルム。
［８］（工程１）成分（ｉ）〜（ｖ）及び必要に応じて成分（ｖｉ）を混合して混合物を得る混合工程と、
（工程２）前記工程１で得られた混合物を８００〜１０００℃で加熱する加熱工程とを有する、
［１］〜［５］の組成物の製造方法。
Examples of the present invention include the following [1] to [8].
[1] (i) alumina, (ii) at least one selected from the group consisting of silica and titanium oxide, and (iii) platinum, platinum compound, palladium, palladium compound, iridium, iridium compound, rhodium and rhodium compound A health promoting composition for generating photons and ions comprising at least one selected from the group consisting of: (iv) celsian and (v) steatite.
[2] The composition according to [1], further comprising (vi) at least one selected from the group consisting of silver, a silver compound, gold, and a gold compound.
[3] The composition according to [1] or [2], comprising 0.0015 to 0.030 part by weight of component (iii) in 100 parts by weight of the composition.
[4] The composition according to [2], comprising 1.5 to 30 parts by weight of component (vi) in 100 parts by weight of the composition.
[5] The composition according to any one of [1] to [3], wherein component (iii) is platinum or a platinum compound.
[6] A fiber comprising the composition according to any one of [1] to [5].
[7] A film comprising the composition according to any one of [1] to [5].
[8] (Step 1) A mixing step of mixing components (i) to (v) and optionally component (vi) to obtain a mixture,
(Step 2) A heating step of heating the mixture obtained in Step 1 at 800 to 1000 ° C.,
The manufacturing method of the composition of [1]-[5].
本発明の組成物は、フォトン及びイオンを発生し、健康増進に役立つ。 The composition of the present invention generates photons and ions, and helps to promote health.
本発明のフォトン及びイオンを発生する健康増進組成物（以下、「本発明の組成物」ともいう。）は、（ｉ）アルミナと、（ｉｉ）シリカ及び酸化チタンからなる群から選択される少なくとも１種と、（ｉｉｉ）白金、白金化合物、パラジウム、パラジウム化合物、イリジウム、イリジウム化合物、ロジウム及びロジウム化合物からからなる群から選択される少なくとも１種と、（ｉｖ）セルシアンと、（ｖ）ステアタイトとを含む。
本発明のフォトン及びイオンを発生する健康増進組成物は、更に、（ｖｉ）銀、銀化合物、金及び金化合物からなる群から選択される少なくとも１種を含むことが好ましい。
The health promoting composition for generating photons and ions of the present invention (hereinafter also referred to as “the composition of the present invention”) is at least selected from the group consisting of (i) alumina, and (ii) silica and titanium oxide. (Iii) at least one selected from the group consisting of (iii) platinum, platinum compounds, palladium, palladium compounds, iridium, iridium compounds, rhodium and rhodium compounds, (iv) celsian, and (v) steatite Including.
The health promoting composition for generating photons and ions of the present invention preferably further comprises (vi) at least one selected from the group consisting of silver, silver compounds, gold and gold compounds.
＜成分（ｉ）アルミナ＞
「アルミナ」（Ａｌ2Ｏ3）は、焼結性に優れる純度９９．９％以上の高純度アルミナ（酸化アルミニウム）を用いるのが好ましい。アルミナとして、上市されている粉末状の高純度アルミナを用いることができる。前記成分（ｉ）の含有量は、組成物１００重量部中、好ましくは２０〜６０重量部、より好ましくは３０〜５０重量部である。また、前記成分（ｉ）の粒径は、本発明の組成物を使用する製品及び使用する態様に依存するが、通常の粒径、例えば数μm以下のものを用いることができる。繊維に混入させて用いる場合は、前記成分（ｉ）の粒径は、その繊維径に依存して、２μm以下、好ましくは１．５μm以下、より好ましくは１．０μm以下、例えば約０．３μmの粒径に調整することが好ましい。なお、粒径は、レーザー回折散乱法により求めた値である。
<Component (i) Alumina>
As the “alumina” (Al 2 O 3 ), it is preferable to use high-purity alumina (aluminum oxide) having a purity of 99.9% or more which is excellent in sinterability. As alumina, commercially available powdery high-purity alumina can be used. The content of the component (i) is preferably 20 to 60 parts by weight, more preferably 30 to 50 parts by weight in 100 parts by weight of the composition. Moreover, although the particle diameter of the said component (i) depends on the product which uses the composition of this invention, and the aspect to be used, a normal particle diameter, for example, a several micrometer or less thing can be used. When mixed and used in the fiber, the particle diameter of the component (i) depends on the fiber diameter and is 2 μm or less, preferably 1.5 μm or less, more preferably 1.0 μm or less, for example about 0.3 μm. It is preferable to adjust to the particle size. The particle diameter is a value obtained by a laser diffraction scattering method.
＜成分（ｉｉ）シリカ及び酸化チタンからなる群から選択される少なくとも１種＞
「シリカ」（ＳｉＯ2）は、純度９９．８％以上の高純度シリカが好ましく、上市されている、例えば超微粒子状無水シリカを用いることができる。シリカの粒径は、前記成分（ｉ）と同様である。
「酸化チタン」は、酸化チタン（ＩＶ）（ＴｉＯ２）をいう。酸化チタンの粒径は、前記成分（ｉ）と同様である。
成分（ｉｉ）の含有量は、組成物１００重量部中、好ましくは４０〜７８重量部、より好ましくは５０〜６５重量部含有される。
成分（ｉｉ）としてはシリカと酸化チタンとを組み合わせて用いることが好ましい。
<Component (ii) At least one selected from the group consisting of silica and titanium oxide>
“Silica” (SiO 2 ) is preferably high-purity silica having a purity of 99.8% or more. For example, ultrafine anhydrous silica can be used. The particle size of silica is the same as that of the component (i).
“Titanium oxide” refers to titanium oxide (IV) (TiO 2 ). The particle size of titanium oxide is the same as that of the component (i).
The content of component (ii) is preferably 40 to 78 parts by weight, more preferably 50 to 65 parts by weight, in 100 parts by weight of the composition.
As component (ii), it is preferable to use a combination of silica and titanium oxide.
＜成分（ｉｉｉ）白金、白金化合物、パラジウム、パラジウム化合物、イリジウム、イリジウム化合物、ロジウム及びロジウム化合物からからなる群から選択される少なくとも１種＞
白金化合物、パラジウム化合物、イリジウム化合物、ロジウム化合物における化合物の形態としては、有機酸塩、無機酸塩、ハロゲン化物、酸化物、水酸化物、アンモニア化合物等が挙げられる。
<Component (iii) At least one selected from the group consisting of platinum, platinum compounds, palladium, palladium compounds, iridium, iridium compounds, rhodium and rhodium compounds>
Examples of the form of the compound in the platinum compound, palladium compound, iridium compound, and rhodium compound include organic acid salts, inorganic acid salts, halides, oxides, hydroxides, and ammonia compounds.
成分（ｉｉｉ）は、好ましくは、コロイドの形態で添加される。酸素と水素とを吸着するいわゆるコロイド活性化を期待できるからである。成分（ｉｉｉ）としては、粒径約０．７〜４ｎｍ（７〜４０Å）で、例えば塩酸溶液中にコロイド分散させた、成分（ｉｉｉ）の分散コロイド（以下、成分（ｉｉｉ）コロイドという）を用いることが好ましい。成分（ｉｉｉ）コロイドの調製方法は、慣用の方法を用いることができる。例えば、商業的に上市されている、例えば白金１重量％含有の白金コロイド溶液を用いることができる。 Component (iii) is preferably added in the form of a colloid. This is because so-called colloidal activation that adsorbs oxygen and hydrogen can be expected. As component (iii), a dispersed colloid of component (iii) (hereinafter referred to as component (iii) colloid) having a particle size of about 0.7 to 4 nm (7 to 40 mm) and dispersed in, for example, a hydrochloric acid solution is used. It is preferable to use it. As a method for preparing the component (iii) colloid, a conventional method can be used. For example, a commercially available platinum colloidal solution containing, for example, 1% by weight of platinum can be used.
成分（ｉｉｉ）はコロイド中に、好ましくは０．１〜５重量％、より好ましくは０．５〜２重量％、さらに好ましくは０．８〜１．２重量％含有されるものが用いられ、成分（ｉｉｉ）は、本発明の組成物１００重量部中、金属として、好ましくは０．００１５〜０．０３０重量部、より好ましくは０．００３〜０．０１２重量部含まれる。
成分（ｉｉｉ）としては、白金又は白金化合物が好ましい。
Component (iii) is preferably used in a colloid containing 0.1 to 5% by weight, more preferably 0.5 to 2% by weight, still more preferably 0.8 to 1.2% by weight, Component (iii) is preferably contained in an amount of 0.0015 to 0.030 parts by weight, more preferably 0.003 to 0.012 parts by weight, as a metal, in 100 parts by weight of the composition of the present invention.
Component (iii) is preferably platinum or a platinum compound.
＜成分（ｉｖ）セルシアン＞
セルシアンは、ＢａＯ・Ａｌ２Ｏ３・２ＳｉＯ２の構造を有するセラミックスである。セルシアンの製造方法としては、公知の製造方法が挙げられるが、たとえば、ＢａＣＯ３、α−Ａｌ２Ｏ３、及びＳｉＯ２を原料として用いて、焼成を行なうことが挙げられる。
成分成分（ｉｖ）は、本発明の組成物１００重量部中、好ましくは０．１〜５重量部、より好ましくは１〜２．５重量部含まれる。
<Component (iv) Celsian>
Celsian is a ceramic having a structure of BaO · Al 2 O 3 · 2SiO 2. Examples of the production method of celsian include known production methods, and examples thereof include firing using BaCO 3 , α-Al 2 O 3 , and SiO 2 as raw materials.
Component component (iv) is contained in 100 parts by weight of the composition of the present invention, preferably 0.1 to 5 parts by weight, more preferably 1 to 2.5 parts by weight.
＜成分（ｖ）ステアタイト＞
ステアタイトは、ＭｇＯ・ＳｉＯ２の構造を有するセラミックスであり、プロトエンスタタイトであることが好ましい。ステアタイトの製造方法としては、公知の製造方法が挙げられるが、たとえば、タルクを原料として用いて、焼成を行なうことが挙げられる。
成分成分（ｖ）は、本発明の組成物１００重量部中、好ましくは０．１〜５重量部、より好ましくは１〜２．５重量部含まれる。
<Component (v) Steatite>
Steatite is a ceramic having a structure of MgO · SiO 2 , and is preferably protoenstatite. As a manufacturing method of a steatite, a well-known manufacturing method is mentioned, For example, baking using talc as a raw material is mentioned.
Component component (v) is preferably contained in 0.1 to 5 parts by weight, more preferably 1 to 2.5 parts by weight, in 100 parts by weight of the composition of the present invention.
＜成分（ｖｉ）銀、銀化合物、金及び金化合物からなる群から選択される少なくとも１種＞
任意成分（ｖｉ）は、粉末の形態で用いることが好ましく、上市されている銀又は金およびそれらの化合物の粉末を用いることができる。本発明の組成物１００重量部中に、金又は銀の量として、０〜３０重量部、好ましくは１．５〜３０重量部、より好ましくは１．５〜１５重量部、さらに好ましくは２．１〜６．０重量部含まれる。
<Component (vi) At least one selected from the group consisting of silver, silver compound, gold and gold compound>
The optional component (vi) is preferably used in the form of a powder, and commercially available powders of silver or gold and their compounds can be used. The amount of gold or silver in 100 parts by weight of the composition of the present invention is 0 to 30 parts by weight, preferably 1.5 to 30 parts by weight, more preferably 1.5 to 15 parts by weight, and still more preferably 2. 1 to 6.0 parts by weight are included.
＜その他の成分＞
本発明の組成物は、窒化ケイ素を含むことができる。窒化ケイ素は、水素の働きをよくし、水素イオンの移動方向を特定の方向に規制する役割をするものと考えられている。ただし、窒化ケイ素を含有させる場合は、本発明の組成物１００重量部中に、３重量部以下の量が好ましい。
その他、溶媒、結合剤、安定化剤等の添加剤等を含んでいてもよい。
<Other ingredients>
The composition of the present invention can comprise silicon nitride. Silicon nitride is thought to play a role of improving the action of hydrogen and regulating the movement direction of hydrogen ions in a specific direction. However, when silicon nitride is contained, an amount of 3 parts by weight or less is preferable in 100 parts by weight of the composition of the present invention.
In addition, additives such as a solvent, a binder, and a stabilizer may be included.
＜製造方法＞
本発明の組成物は、
（工程１）成分（ｉ）〜（ｖ）及び必要に応じて成分（ｖｉ）を混合して混合物を得る混合工程と、
（工程２）前記工程１で得られた混合物を８００〜１０００℃で加熱する加熱工程とを有する、製造方法により得ることができる。
最初に（工程１）混合工程を行なう。具体的には、成分（ｉ）と、成分（ｉｉ）とを、それぞれ、コロイドに分散させた成分（ｉｉｉ）と混合し、次いで、前記混合物に成分（ｉｖ）と成分（ｖ）とを加えて混合し、必要であれば、これに成分（ｖｉ）の粉末を混合する。または、所定量の成分（ｉ）にのみ、所定量の成分（ｉｉｉ）のコロイドを加え、つぎに成分（ｉｉ）、並びに成分（ｉｖ）及び成分（ｖ）を加えて撹拌混合し、必要であれば、さらに成分（ｖｉ）を加えて、再度撹拌混合する。
<Manufacturing method>
The composition of the present invention comprises:
(Step 1) a mixing step of mixing components (i) to (v) and optionally component (vi) to obtain a mixture;
(Process 2) It can obtain by the manufacturing method which has a heating process which heats the mixture obtained at the said process 1 at 800-1000 degreeC.
First (step 1) a mixing step is performed. Specifically, component (i) and component (ii) are each mixed with component (iii) dispersed in a colloid, and then component (iv) and component (v) are added to the mixture. If necessary, the powder of component (vi) is mixed therewith. Alternatively, a predetermined amount of the component (iii) colloid is added only to the predetermined amount of the component (i), and then the component (ii), the component (iv) and the component (v) are added and stirred and mixed. If so, add further component (vi) and stir and mix again.
次に、（工程２）加熱工程を行なう。具体的には、上記混合工程で得られた混合物を８００〜１０００℃で１５〜２０分間加熱する。この工程において、成分（ｉｉｉ）が、成分（ｉ）に担持される、または成分（ｉ）及び（ｉｉ）に担持されるものと考えられる。 Next, (Step 2) a heating step is performed. Specifically, the mixture obtained in the mixing step is heated at 800 to 1000 ° C. for 15 to 20 minutes. In this step, it is considered that component (iii) is supported on component (i) or supported on components (i) and (ii).
さらに、本発明の組成物は、微粒子粉末として製造することができ、粒径０．１〜２．０μmが好ましく、０．２〜１．０μmがより好ましい。なお、粒径は、レーザー回折散乱法により求めた値である。粉末とする場合は、工程１で得られた混合物を任意に噴霧可能な流動性を有するまで溶媒などで希釈し、噴霧した後、工程２の加熱工程を行なう。希釈する溶媒は、本発明の組成物の効果を阻害しない溶媒であれば用いることができ、例えば、純水、アルコールなどが挙げられる。分散性を向上させるため、公知の分散剤を添加することができる。 Furthermore, the composition of the present invention can be produced as a fine particle powder, preferably having a particle size of 0.1 to 2.0 μm, more preferably 0.2 to 1.0 μm. The particle size is a value obtained by a laser diffraction scattering method. In the case of powder, the mixture obtained in step 1 is diluted with a solvent or the like until it has a fluidity that can be arbitrarily sprayed, sprayed, and then the heating step in step 2 is performed. The solvent to be diluted can be used as long as it does not inhibit the effect of the composition of the present invention, and examples thereof include pure water and alcohol. In order to improve dispersibility, a known dispersant can be added.
＜特性＞
（１）フォトンの発生
図１に示すように、本発明の組成物は発光する。すなわちフォトンを発生する。
（２）イオンの発生
図２に示すように、本発明の組成物はイオンを発生する。
これらの特性が、本願発明の健康増進効果に影響を与えているものと考えられる。
<Characteristic>
(1) Generation of photons As shown in FIG. 1, the composition of the present invention emits light. That is, photons are generated.
(2) Ion generation As shown in FIG. 2, the composition of the present invention generates ions.
These characteristics are considered to affect the health promotion effect of the present invention.
＜用途＞
本発明の組成物は、健康増進用途に用いられる。
より具体的には、血行が良くなる、過酸化脂質が抑制できる、運動後の乳酸の生成を抑制できる、免疫力が安定するといった健康増進用途が挙げられる。
本発明の組成物は、上述のように、フォトン及びイオンを発生するため、本発明の組成物を用いると、人間の体内でＮＯが発生すると考えられ、発生したＮＯが血管を弛緩させ、血行などに影響を与えるため、上記の健康増進用途に好適に用いることができると考えられる。
<Application>
The composition of the present invention is used for health promotion applications.
More specifically, there are health promotion uses such as improved blood circulation, lipid peroxide suppression, production of lactic acid after exercise, and stabilization of immunity.
Since the composition of the present invention generates photons and ions as described above, it is considered that NO is generated in the human body when the composition of the present invention is used, and the generated NO relaxes blood vessels and causes blood circulation. Therefore, it can be suitably used for the above health promotion application.
〈製品〉
本発明の組成物は、繊維及びフィルム等に含ませることができる。
化学繊維及びフィルムに含ませる場合は、本発明の組成物を含むマスターバッチを使用することもできる。マスターバッチを製造する方法は、本発明の組成物を、粉体状にして合成高分子材料に練り込む方法又は分散液の状態にして合成高分子材料に混合する方法等が挙げられる。このとき、混合物中の本発明の組成物は０．１〜２５重量％とすることができる。
<Product>
The composition of the present invention can be contained in fibers and films.
When included in chemical fibers and films, a masterbatch containing the composition of the present invention can also be used. Examples of the method for producing a master batch include a method in which the composition of the present invention is powdered and kneaded into the synthetic polymer material, or a dispersion is mixed with the synthetic polymer material. At this time, the composition of this invention in a mixture can be 0.1-25 weight%.
１．繊維
本発明の組成物は、繊維に含ませた製品とすることができる。
繊維としては、天然繊維、化学繊維が挙げられ、天然繊維としては、コットン、ウール、シルク、麻等が挙げられ、化学繊維としては、セルロース系、ナイロン等のポリアミド系、ビニロン等のポリビニルアルコール系、ポリ塩化ビニリデン系、ポリ塩化ビニル系、ポリエステル系、アクリル系、ポリオレフィン系、ポリウレタン系等が挙げられる。これらは、１種単独で用いても、２種以上組み合わせて用いてもよい。たとえば、天然繊維と本発明の組成物を含む化学繊維とを混紡してもよい。
1. Fiber The composition of the present invention can be a product contained in a fiber.
Examples of fibers include natural fibers and chemical fibers. Examples of natural fibers include cotton, wool, silk, and linen. Examples of chemical fibers include polyamides such as cellulose and nylon, and polyvinyl alcohols such as vinylon. , Polyvinylidene chloride, polyvinyl chloride, polyester, acrylic, polyolefin, polyurethane and the like. These may be used alone or in combination of two or more. For example, natural fibers and chemical fibers containing the composition of the present invention may be blended.
本発明の組成物を繊維に含ませるためには、本発明の組成物を繊維に練り込む、又は繊維表面に付着させることができる。本発明の組成物を繊維に練り込む方法としては、繊維に対し、本発明の組成物を例えば０．１〜２５重量％、好ましくは０．１〜３重量％、より好ましくは０．３〜１．５重量％混合し、繊維溶融して混合物として、この混合物を慣用の紡糸法、例えば溶融紡糸、乾式紡糸、湿式紡糸を用いて紡糸することが挙げられる。本発明の組成物を含むマスターバッチを製造してから紡糸することも好ましい。本発明の組成物を繊維表面に付着させる方法としては、スプレー、ディッピング又はコーティングする方法を採用することができる。
繊維には、本発明の組成物の他、酵素、ヒアルロン酸等の保湿剤等を練り込むことができる。
本発明の組成物を含む繊維は、寝具、衣類等に好適に用いられる。
In order to include the composition of the present invention in the fiber, the composition of the present invention can be kneaded into the fiber or adhered to the fiber surface. As a method of kneading the composition of the present invention into fibers, the composition of the present invention is, for example, 0.1 to 25% by weight, preferably 0.1 to 3% by weight, more preferably 0.3 to Mixing by 1.5% by weight, melting the fiber, and preparing the mixture as a mixture may be performed by spinning the mixture using a conventional spinning method such as melt spinning, dry spinning, or wet spinning. It is also preferred to produce a masterbatch containing the composition of the invention before spinning. As a method for attaching the composition of the present invention to the fiber surface, a method of spraying, dipping or coating can be employed.
In addition to the composition of the present invention, humectants such as enzymes and hyaluronic acid can be kneaded into the fibers.
The fiber containing the composition of the present invention is suitably used for bedding, clothing and the like.
２．フィルム
本発明の組成物は、フィルムに含ませた製品とすることができる。
フィルムとしては、ポリオレフィン、ポリ塩化ビニル、ポリ塩化ビニリデン、ポリエチレンテレフタラート、ポリウレタン等の熱可塑性樹脂が挙げられる。
本発明の組成物をフィルムに含ませる方法としては、溶融状態の上記樹脂に粉末状の本発明の組成物を添加し混合した後、公知の方法にて成形することが挙げられる。本発明の組成物を含むマスターバッチを上記熱可塑性樹脂と混合し成形することもできる。
本発明の組成物を含むフィルムは、サージカルテープに好適に用いられる。
2. Film The composition of the present invention can be a product contained in a film.
Examples of the film include thermoplastic resins such as polyolefin, polyvinyl chloride, polyvinylidene chloride, polyethylene terephthalate, and polyurethane.
As a method for including the composition of the present invention in a film, the powdery composition of the present invention is added to the molten resin and mixed, and then molded by a known method. A master batch containing the composition of the present invention can be mixed with the thermoplastic resin and molded.
The film containing the composition of the present invention is suitably used for surgical tape.
なお、上記繊維及びフィルムの製造において、必要に応じて、例えば、酸化マグネシウム、マイカ、炭酸カルシウム、ゼオライト等の触媒、可塑材、紫外線吸収剤、充填剤、着色剤、着色防止剤、難燃剤、ブリードアウト防止剤、安定剤、耐熱剤、蛍光増白剤等の各種の添加剤を配合することができる。 In the production of the fiber and film, if necessary, for example, a catalyst such as magnesium oxide, mica, calcium carbonate, zeolite, plasticizer, ultraviolet absorber, filler, colorant, anti-coloring agent, flame retardant, Various additives such as a bleed-out preventing agent, a stabilizer, a heat resistance agent, and a fluorescent brightening agent can be blended.
以下、本発明を実施例及び比較例により更に詳細に説明するが、本発明はこれら実施例により限定されるものではない。 EXAMPLES Hereinafter, although an Example and a comparative example demonstrate this invention further in detail, this invention is not limited by these Examples.
〔実施例１〕組成物の製造（１）
市販のアルミナ、シリカ及び酸化チタン（チタニア）を、いずれも粒度１μm以下になるように粒度調整し、次いで、それぞれ３３重量部ずつに対し、白金１％含有の白金コロイド溶液（粒径４０オングストローム）０．２４９重量部ずつ（すなわち白金として０．００２４重量部づつ）を別々に混合し、コロイド混合物を作製した。つぎに、このコロイド混合物９９．７５重量部に、粒径０．２〜１．０μm、平均粒径０．７μmの銀粉末３．０重量部、粉砕したセルシアン（ＢａＯ・Ａｌ２Ｏ３・２ＳｉＯ２）１．５重量部及び粉砕したプロトエンスタタイト１．５重量部を加え混合物を得た。したがって、本実施例の組成物における各物質の配合比は、アルミナ：３１．４２８重量％、シリカ：３１．４２８重量％、酸化チタン：３１．４２８重量％、白金：０．００２重量％、銀：２．８５７重量％、セルシアン（ＢａＯ・Ａｌ２Ｏ３・２ＳｉＯ２）１．４２９重量％及びプロトエンスタタイト１．４２９重量％であった。
得られた混合物を、噴霧可能な流動性を有するまで純水で希釈し、噴霧して均一に分散させ、その後、８００℃で２０分間加熱し、微粒子粉末形態の組成物を製造した。
[Example 1] Production of composition (1)
The particle size of commercially available alumina, silica and titanium oxide (titania) was adjusted so that the particle size would be 1 μm or less, and then a platinum colloid solution containing 1% platinum (particle size: 40 Å) for each 33 parts by weight. 0.249 parts by weight (that is, 0.0024 parts by weight as platinum) was separately mixed to prepare a colloid mixture. Next, 99.75 parts by weight of the colloidal mixture, 3.0 parts by weight of silver powder having a particle size of 0.2 to 1.0 μm and an average particle size of 0.7 μm, and ground celsian (BaO.Al 2 O 3 .2SiO 2 ) 1.5 parts by weight and 1.5 parts by weight of pulverized protoenstatite were added to obtain a mixture. Therefore, the compounding ratio of each substance in the composition of this example is alumina: 31.428% by weight, silica: 31.428% by weight, titanium oxide: 31.428% by weight, platinum: 0.002% by weight, silver : 2.857 wt%, celsian (BaO.Al 2 O 3 .2SiO 2 ) 1.429 wt% and protoenstatite 1.429 wt%.
The obtained mixture was diluted with pure water until it had sprayable fluidity, sprayed and uniformly dispersed, and then heated at 800 ° C. for 20 minutes to produce a composition in the form of fine particle powder.
〔実施例２〕 組成物の製造（２）
組成物中の含有量を、アルミナ：４７重量％、酸化チタン（チタニア）：４７重量％、白金：０．０３重量％及び銀：２．９７重量％、セルシアン（ＢａＯ・Ａｌ２Ｏ３・２ＳｉＯ２）１．５重量％及びプロトエンスタタイト１．５重量％に変更した以外は、実施例１と同様にして、組成物を形成した。
[Example 2] Production of composition (2)
The content in the composition was as follows: alumina: 47% by weight, titanium oxide (titania): 47% by weight, platinum: 0.03% by weight and silver: 2.97% by weight, celsian (BaO.Al 2 O 3 · 2SiO) 2 ) A composition was formed in the same manner as in Example 1 except for changing to 1.5% by weight and 1.5% by weight of protoenstatite.
〔実施例３〕 組成物の製造（３）
実施例１において、組成物を微粉末状態にする代わりに、φ６ｍｍの球形とした以外は、実施例１と同様にして組成物を形成した。
[Example 3] Production of composition (3)
In Example 1, a composition was formed in the same manner as in Example 1 except that the composition was made into a spherical shape having a diameter of 6 mm instead of being in a fine powder state.
［応用例１］
実施例１の組成物を、ポリエステル１００重量部に対して６重量部混合してマスターバッチを製造した。このマスターバッチをポリエステルに対して１０重量％混合し、溶融紡糸することにより、７５デニールの糸及び３０デニールの糸を製造した。
[Application Example 1]
A master batch was prepared by mixing 6 parts by weight of the composition of Example 1 with 100 parts by weight of polyester. The masterbatch was mixed at 10% by weight with respect to the polyester and melt-spun to produce 75 denier yarn and 30 denier yarn.
［応用例２］
応用例１で得られた繊維を用いて、以下の布を製造した。
繊維混率：応用例１の繊維３０％、綿７０％
[Application 2]
Using the fiber obtained in Application Example 1, the following fabric was produced.
Fiber mixing ratio: 30% fiber of application example 1, 70% cotton
［応用例３］
応用例１で得られた繊維を用いて、以下の布を製造した。
繊維混率：応用例１の繊維１００％、
[Application Example 3]
Using the fiber obtained in Application Example 1, the following fabric was produced.
Fiber mixing ratio: 100% of fiber of application example 1,
［測定例１：発光量の測定］
測定装置：極微弱発光分光装置ＣＬＡ−ＦＳ４（東北電子産業株式会社製）及び試料室ＣＬＳ−ＳＴ４（東北電子産業株式会社製）を用いた。
測定条件：応用例１で得られた繊維０．０８２８ｇをφ５０ステンレスシャーレに入れ、４０ｍｍφのマスクを被せて、空気中、１００℃で発光量を測定した。
結果を図１に示す。
図１より、本発明の組成物を含む繊維は、発光し、フォトンを発生していることがわかる。
[Measurement Example 1: Measurement of luminescence]
Measuring device: Extremely weak emission spectrometer CLA-FS4 (made by Tohoku Electronics Industry Co., Ltd.) and sample chamber CLS-ST4 (made by Tohoku Electronics Industry Co., Ltd.) were used.
Measurement conditions: 0.0828 g of the fiber obtained in Application Example 1 was put in a φ50 stainless steel dish, covered with a 40 mmφ mask, and the amount of luminescence was measured at 100 ° C. in air.
The results are shown in FIG.
FIG. 1 shows that the fiber containing the composition of the present invention emits light and generates photons.
［測定例２：イオンの測定］
測定装置：ＭＯＤＥＬ−ＳＮ（日本機能性イオン協会標準器）
本体構造：円筒型コンデンサー
計測部：負帰還型振動容量電位計
測定方法：センサー部先端にＳＵＳ製の箱を設置し、その中に実施例３のφ６ｍｍの球形の試料５０ｇを入れて、２１℃、湿度６１％、気圧１０１７ｈｐａの条件で、測定した。なお、箱の空気導入側の筒の先端に、空気清浄機（ヘパフィルター）及びイオンフィルターを設置して行なった。
結果を図２に示す。
図２より、本発明の組成物は、イオンを発生していることがわかる。
[Measurement Example 2: Ion Measurement]
Measuring device: MODEL-SN (Japan Functional Ion Association Standard)
Body structure: Cylindrical condenser Measuring part: Negative feedback type vibration capacity potentiometer Measuring method: A SUS box is installed at the tip of the sensor part, and a spherical sample of φ6 mm of Example 3 is put in it, and the temperature is 21 ° C. The measurement was performed under the conditions of a humidity of 61% and an atmospheric pressure of 1017 hpa. An air purifier (hepa filter) and an ion filter were installed at the tip of the cylinder on the air introduction side of the box.
The results are shown in FIG.
FIG. 2 shows that the composition of the present invention generates ions.
［評価例１：血液中の乳酸塩濃度の測定］
地方競技の訓練レベルの１６〜３５歳までの自転車競技選手を２４名（男性）選抜し、２４名の選手を１２名ずつの２群に分け、５分毎に５０ワットずつ上げるというリズムで周期的最大エルグ計測（疲労度、筋肉活動量を測定すること）を行ない、その都度、毛細血管血液中の乳酸塩を抽出測定する。１週間後、同じ条件下で第２回目の試験を繰り返し、この時一方の群には、応用例１の繊維を用いたユニフォームを着用させ、もう一方の群には中性の繊維を用いたものを着用させる。応用例１の繊維が及ぼす実効果以外の全ての影響を避けるため、研究者にも試験を受ける選手にも内容を伏せて二重盲検テストを実施した（群間比較）。
使用するユニフォームにおいて応用例１の繊維は内側に施されている。この二重盲検テストを実施するに当たり、肌触りも外見も全く同様のユニフォームを２種類使用した。
結果を表１に示す。
[Evaluation Example 1: Measurement of lactate concentration in blood]
Cycles with a rhythm of selecting 24 (male) bicycle athletes from the age 16-35 age group at the local sport training level, dividing the 24 athletes into two groups of 12 each and raising 50 watts every 5 minutes Maximum erg measurement (measuring fatigue and muscle activity) is performed, and lactate in capillary blood is extracted and measured each time. One week later, the second test was repeated under the same conditions. At this time, one group was allowed to wear a uniform using the fibers of Application Example 1, and the other group was neutral fibers. Wear things. In order to avoid all the effects other than the actual effects of the fiber of Application Example 1, a double-blind test was conducted with the contents both faced by researchers and athletes who took the test (comparison between groups).
In the uniform to be used, the fibers of Application Example 1 are applied on the inside. In carrying out this double-blind test, two types of uniforms having the same touch and appearance were used.
The results are shown in Table 1.
乳酸は、運動をする際に、蓄積された糖分が分解されると同時に作り出されるものであって、乳酸閾値と呼ばれる乳酸を分解する限界値を超えたときに、疲労を感じたり筋肉の動作を妨げるという研究がなされている。
表１から、中性繊維を用いたユニフォームを着用した選手の結果の平均値から、２００Ｗと２５０Ｗの運動量の間に乳酸塩の減少率がプラスからマイナスに代わることから、乳酸閾値があると考えられる。しかしながら、応用例１の繊維を用いたユニフォームを着用した選手の平均値においては、この乳酸閾値を超えた２５０Ｗ及び３００Ｗの運動をした場合であっても、血液中の乳酸塩の量が減少している。したがって、応用例１の繊維を用いたユニフォームを着用して運動すると、乳酸閾値が上がり、運動による疲労を感じにくいと考えられる。
Lactic acid is produced at the same time as the accumulated sugar is decomposed when exercising, and when it exceeds a limit value for degrading lactic acid called the lactic acid threshold, it feels tired and moves muscles. Research has been done to prevent it.
From Table 1, from the average value of the results of athletes wearing uniforms using neutral fibers, the lactate reduction rate changes between plus and minus between 200W and 250W momentum, so there is a lactic acid threshold It is done. However, in the average value of athletes wearing uniforms using the fibers of Application Example 1, the amount of lactate in the blood decreases even when 250 W and 300 W exercise exceeding this lactic acid threshold is performed. ing. Therefore, it is thought that when wearing a uniform using the fiber of Application Example 1 and exercising, the lactic acid threshold increases and it is difficult to feel fatigue due to exercise.
［評価例２：好中球及びリンパ球能力の測定］
健康人８名（男性４名：１８〜４０歳、女性４名：２２〜３８歳）の末梢血好中球・リンパ球を用い、実験体として応用例２（３０％）の布地及び応用例３（１００％）の布地を用いる。応用例２（３０％）の布地及び応用例３（１００％）の布地を３７℃に保ちながら、それぞれ細胞浮遊液ならびにＤＨＡ（ドコサヘキサエン酸）含有試験管を布で外から包み込んで接触（外包法）させた後、下記の検査項目の測定を行なった。接触時間は５、３０、６０、９０、１２０分とした。検査項目としては、好中球細胞質内［Ｃａ２＋］ｉの測定の他、好中球の遊走能、貪食、およびＯ２ −産生能の測定、リンパ球については、３種のｍｉｔｏｇｅｎｓ（有糸分裂促進因子）に対するｂｌａｓｔｏｇｅｎｅｓｉｓ（リンパ球幼若化）を測定した。
結果を表２に示す。
[Evaluation Example 2: Measurement of neutrophil and lymphocyte ability]
Fabrics and application examples of application example 2 (30%) using peripheral blood neutrophils / lymphocytes of 8 healthy persons (4 males: 18-40 years old, 4 females: 22-38 years old) 3 (100%) fabric is used. While maintaining the fabric of Application Example 2 (30%) and the fabric of Application Example 3 (100%) at 37 ° C., the cell suspension and the DHA (docosahexaenoic acid) -containing test tube are each wrapped with a cloth and contacted (encapsulation method) ), The following inspection items were measured. The contact time was 5, 30, 60, 90, 120 minutes. The test items include measurement of neutrophil cytoplasmic [Ca 2+ ] i, measurement of neutrophil migration ability, phagocytosis, and O 2 − production ability, and three types of mitogens (threads). Blastogenesis against mitogens was measured.
The results are shown in Table 2.
表２中、リンパ球は、０分値が対照値となり、他の好中球機能はそれぞれの時間ごとの対照値が用いられた。
表２から、ｆＭＬＰの好中球［Ｃａ２＋］ｉは増加しなかったが、ｉｏｎｏｍｙｃｉｎ添加あるいはｒｅｓｔｉｎｇの好中球では、布地と試験管の接触時間が５分で増加し、６０分で５分値と同様あるいは著しい増加のピークが認められた。
In Table 2, the 0 minute value was the control value for lymphocytes, and the control value for each hour was used for the other neutrophil functions.
From Table 2, fMLP neutrophils [Ca 2+ ] i did not increase, but in the case of neutrophils with or without ionomycin, the contact time between the fabric and the test tube increased in 5 minutes, and 5 minutes in 60 minutes. Similar to the value or a peak of significant increase was observed.
次に、好中球遊走能は、接触時間５分で統計的有意差は認められなかったが、若干亢進傾向が見られ、６０分で軽度な亢進が認められた。好中球貪食能への影響も、ほぼ遊走能と同傾向を示し、５分で若干亢進傾向を示し、６０分で有意の亢進が見られた。好中球のＯ２ −産生能は、５分で軽度の増加を示し、６０分でピークが見られ、応用例３の布のほうが、応用例２の布より強い影響を示した。
リンパ球幼若化への影響は、ＰＨＡ、ＣｏｎＡ、ＰＷＭいずれの５分の接触時間で軽度の亢進を示し、６０分でピークが見られた（ＣｏｎＡ、ＰＷＭに関しては表省略）。
これらの結果から、応用例２及び３の布は、免疫の能力を高める効果があると考えられる。
Next, although the neutrophil migration ability showed no statistically significant difference at a contact time of 5 minutes, a slight increase tendency was observed, and a slight increase was observed at 60 minutes. The effect on neutrophil phagocytic ability was also almost the same as the migration ability, showing a slight increase tendency at 5 minutes, and a significant increase at 60 minutes. O 2 neutrophil - Sanseino showed an increase in mild at 5 minutes, peaks were found at 60 min, more fabric applications 3 exhibited a strong effect than fabrics applications 2.
The effect on lymphocyte blastogenesis was mildly increased at a contact time of 5 minutes for any of PHA, ConA, and PWM, and a peak was observed at 60 minutes (not shown for ConA and PWM).
From these results, the fabrics of Application Examples 2 and 3 are considered to have an effect of enhancing the immunity ability.
［評価例３：過酸化脂質形成反応への影響の測定］
不飽和脂肪酸の原液を９５％エタノールで２００倍に希釈し、試験管に注入する。
下敷法により、希釈した溶液の入った試験管１本毎の下にそれぞれ応用例２（３０％）の布地及び応用例３（１００％）の布地を敷き接触させる。その後、日光を６時間照射させ、各試験管内の溶液から２０μｌを採り、二波長分光光度計にてそれぞれ過酸化脂質値を測定した。また、前述試験を８回行い、その結果の平均値を測定値とした。
結果を表３に示す。
[Evaluation Example 3: Measurement of influence on lipid peroxide formation reaction]
The unsaturated fatty acid stock solution is diluted 200-fold with 95% ethanol and injected into a test tube.
By the underlay method, the fabric of Application Example 2 (30%) and the fabric of Application Example 3 (100%) are placed under and contacted with each test tube containing the diluted solution. Then, it was made to irradiate with sunlight for 6 hours, 20 microliters was taken from the solution in each test tube, and the lipid peroxide value was measured with the two wavelength spectrophotometer, respectively. In addition, the above test was performed 8 times, and the average value of the results was taken as the measured value.
The results are shown in Table 3.
吸光度は、光が物体を通さず吸収する場合に数値が上昇する。つまり、試験管内に過酸化脂質などの不純物が高くなる。
表３からは、応用例２の布及び応用例３の布を使用した場合のいずれにおいても、吸光度が減少している。特に応用例３の布は減少率が高い。したがって、応用例２の布及び応用例３の布には、過酸化脂質を減少させる効果があるものと考えられる。
過酸化脂質は、様々な病気や組織障害を引き起こす原因とされているので、本発明の組成物は、それらの病気の予防にも役立つと考えられる。
The absorbance increases when light is absorbed without passing through an object. That is, impurities such as lipid peroxide increase in the test tube.
From Table 3, the absorbance decreased in both cases of using the fabric of application example 2 and the fabric of application example 3. In particular, the reduction rate of the fabric of Application Example 3 is high. Therefore, it is considered that the fabric of application example 2 and the fabric of application example 3 have an effect of reducing lipid peroxide.
Since lipid peroxide is considered to cause various diseases and tissue damage, the composition of the present invention is considered to be useful for preventing these diseases.
〔応用例４〕 実施例１の組成物を含む繊維の製造方法
実施例１で得られた組成物をポリエステルチップに５重量％混入しマスターバッチを作製した。このマスターバッチを繊維紡績時にポリエステルに対して１０重量％混入し繊維（ポリエステル）を作製した。したがって、ポリエステル繊維中の組成物の比率は０．５重量％であった。また、製造した繊維は、Ｉ：長繊維（フィラメント）７５デニール７２フィラメント、及び
II：短繊維（ステープル）６デニール５１mm中空糸であった。
[Application Example 4] Method for Producing Fiber Containing Composition of Example 1 The masterbatch was prepared by mixing 5% by weight of the composition obtained in Example 1 into a polyester chip. This masterbatch was mixed with 10% by weight of polyester during fiber spinning to produce a fiber (polyester). Therefore, the ratio of the composition in the polyester fiber was 0.5% by weight. Further, the manufactured fiber is: I: long fiber (filament) 75 denier 72 filament, and
II: Short fiber (staple) 6 denier 51 mm hollow fiber.
〔応用例５〕 実施例１の組成物を含むパイプの製造
実施例１で得られた組成物をポリエチレンチップに５重量％混入しマスターバッチを作製した。さらに、このマスターバッチをポリエチレンパイプ製作時に１０重量％混入した。したがって、パイプ中の組成物の比率は０．５重量％であった。また、得られたパイプは、直径（外径）５mm、長さ７mmであった。
[Application Example 5] Manufacture of a pipe containing the composition of Example 1 The composition obtained in Example 1 was mixed with polyethylene chips at 5% by weight to prepare a masterbatch. Further, 10% by weight of this master batch was mixed during the production of the polyethylene pipe. Therefore, the proportion of the composition in the pipe was 0.5% by weight. Further, the obtained pipe had a diameter (outer diameter) of 5 mm and a length of 7 mm.
〔応用例６〕 応用例４及び５で得られた繊維及びパイプからの寝具及び寝衣の製造
応用例４及び５で得られた繊維及びパイプから、常法により、以下の寝具及び寝衣を製造した。
（１）シーツ
形状：フラット型、幅１５０cm×長さ２３０cm
繊維混率：応用例４の繊維１００％（ポリエステル）
その他：平織り（縦糸、横糸とも応用例４の繊維１００％）
[Application Example 6] Manufacture of bedding and nightclothes from the fibers and pipes obtained in Application Examples 4 and 5 From the fibers and pipes obtained in Application Examples 4 and 5, the following bedding and nightclothes were prepared in a conventional manner. Manufactured.
(1) Sheet shape: Flat type, width 150cm x length 230cm
Fiber mixing ratio: 100% fiber of application example 4 (polyester)
Others: Plain weave (100% fiber of Application Example 4 for both warp and weft)
（２）毛布
形状：両面起毛型、幅１４０cm×長さ２００cm
繊維混率：起毛部 応用例４の繊維５０％（ポリエステル）、綿５０％
その他：起毛部 応用例４の繊維（ポリエステル）綿混４０番手双糸使用
(2) Blanket Shape: Double-sided raised type, width 140cm x length 200cm
Fiber mixing ratio: Raised portion 50% fiber (polyester) of application example 4, 50% cotton
Others: Brushed part Use of the fiber (polyester) cotton blend 40 count double yarn of application example 4
（３）敷パット
形状：幅９０cm×長さ１８５cm×厚さ２cm、重量１．５kg
繊維混率：中わた 応用例４の繊維１００％（ポリエステル）
側生地 応用例４の繊維１００％生地（ポリエステル）
その他：キルティング加工
(3) laid pad shape: width 90cm x length 185cm x thickness 2cm, weight 1.5kg
Fiber mixing ratio: Medium cotton 100% fiber of application example 4 (polyester)
Side fabric 100% fiber fabric of application example 4 (polyester)
Other: Quilting processing
（４）枕
形状：５分割充填物（パイプ）微調節可能型、幅６０cm×たて５０cm（全体）
成分：充填物 応用例５のパイプ１００％（ポリエチレン）、本体袋 綿１００％、本体カバー 綿１００％
その他：枕の充填物（中味）を５つのメッシュ袋に分割して充填することで、頭の位置の微調節を可能にした構造を有し、５つめのメッシュ袋は本体カバーに装着し、首から肩の部分をサポートする構造を有した。
(4) Pillow Shape: 5-part filling (pipe) fine-adjustable type, width 60 cm x length 50 cm (whole)
Ingredients: Filling Application example 5 pipe 100% (polyethylene), body bag 100% cotton, body cover 100% cotton
Others: The pillow filling (contents) is divided into five mesh bags and filled to allow fine adjustment of the head position. The fifth mesh bag is attached to the body cover. It had a structure to support the neck to shoulder part.
（５）シャツ
形状：丸首長袖
繊維混率：応用例４の繊維９７％（ポリエステル）・ポリウレタン３％生地使用
(5) Shirt shape: Round neck long sleeve Fiber mixing ratio: 97% fiber (polyester) of application example 4 and 3% polyurethane fabric
（６）ズボン
形状：長ズボン
繊維混率：応用例４の繊維９７％（ポリエステル）・ポリウレタン３％生地使用
(6) Trousers Shape: Long trousers Fiber mixing ratio: 97% fiber (polyester) of application example 4 and 3% polyurethane fabric
［評価例４：血液中の硝酸イオン濃度］
Ａ．実験方法
対象：人間ドック入院受診者２０名からなった。
方法：対象を封筒法により、Ｉ群・II群に分けた。対象を以下のように（表１参照）、午後２時より２時間、２種類の寝具および寝衣を用いて午睡させた。午睡中、室温は２４℃に固定し、午睡前１時間は飲水を禁止した。
Ｉ群：第１日目 本発明の寝具及び寝衣（シーツ、毛布、敷パット、枕、シャツ及びズボン）使用
第２日目 通常の寝具及び寝衣（シーツ、毛布、敷パット、枕、シャツ及びズボン）使用
II群：第１日目 通常の寝具及び寝衣使用
第２日目 本発明の寝具及び寝衣使用
[Evaluation Example 4: Nitrate ion concentration in blood]
A. Subjects of the experiment method: Consists of 20 medical checkups.
Method: Subjects were divided into groups I and II by the envelope method. Subjects were allowed to nap using the two types of bedding and nightclothes for 2 hours from 2 pm as follows (see Table 1). During the nap, the room temperature was fixed at 24 ° C., and drinking was prohibited for 1 hour before nap.
Group I: Day 1 Use of bedding and nightclothes (sheets, blankets, mattress pads, pillows, shirts and trousers) of the present invention Day 2 Ordinary bedding and nightclothes (sheets, blankets, mattress pads, pillows, shirts) And pants) use
Group II: Day 1 Use of normal bedding and nightclothes Day 2 Use of bedding and nightclothes of the present invention
なお、通常の寝具及び寝衣は以下のものを使用した。
The normal bedding and nightclothes used were as follows.
（７）シーツ
形状：フラット型、幅１５０cm×長さ２３０cm
繊維混率：綿１００％
その他：平織り（縦糸、横糸とも綿１００％）
(7) Sheet shape: Flat type, width 150cm x length 230cm
Fiber mixing ratio: 100% cotton
Others: Plain weave (100% cotton for both warp and weft)
（８）毛布
形状：両面起毛型、幅１４０cm×長さ２００cm
繊維混率：綿１００％
(8) Blanket Shape: Double-sided brushed type, width 140cm x length 200cm
Fiber mixing ratio: 100% cotton
（９）敷パット
形状：幅９０cm×長さ１８５cm×厚さ２cm、重量１．５kg
繊維混率：中わた 綿１００％、側生地 綿１００％生地
その他：キルティング加工
(9) Cover pad shape: width 90cm x length 185cm x thickness 2cm, weight 1.5kg
Fiber mixing ratio: Cotton 100% cotton, side fabric 100% cotton fabric Others: Quilted
（１０）枕
形状：５分割充填物（パイプ）微調節可能型、幅６０cm×たて５０cm（全体）
成分：充填物 ポリエチレンパイプ１００％、本体袋 綿１００％、
本体カバー 綿１００％
その他：枕の充填物（中味）を５つのメッシュ袋に分割して充填することで、頭の位置の微調節を可能にした構造を有し、５つめのメッシュ袋は本体カバーに装着し、首から肩の部分をサポートする構造を有した。
(10) Pillow Shape: 5-part filling (pipe) fine adjustable type, width 60 cm x length 50 cm (whole)
Ingredients: Filling 100% polyethylene pipe, 100% cotton bag,
Body cover 100% cotton
Others: The pillow filling (contents) is divided into five mesh bags and filled to allow fine adjustment of the head position. The fifth mesh bag is attached to the body cover. It had a structure to support the neck to shoulder part.
（１１）シャツ
形状：丸首長袖
繊維混率：ポリエステル１００％生地使用
(11) Shirt shape: Round neck long sleeve Fiber mixing ratio: 100% polyester fabric
（１２）ズボン
形状：長ズボン
繊維混率：ポリエステル１００％生地使用
期間： １か月間使用
(12) Trousers Shape: Long trousers Fiber mixing ratio: 100% polyester fabric used Period: Used for 1 month
Ｂ．検査項目
１．腋窩体温、体重
２．午睡直前及び午睡開始２時間後に採血して測定した。採血量は３０ml／回であった。全ての対象に検査を表４の如く施行した。
B. Inspection item 1. Axillary body temperature, weight 2. Blood was collected immediately before nap and 2 hours after the start of nap. The amount of blood collected was 30 ml / dose. All subjects were examined as shown in Table 4.
３．橈骨動脈血管径
入院中任意の時間に測定した。
以上検査施行上、特に採血法に於いて組織液の混入があると測定値変動が起き易いために、原則的に、ダブルシリンジ法か留置針設置法によって採血を施行した。
3. Radial artery vessel diameter Measured at any time during hospitalization.
As described above, since the measurement value is likely to fluctuate when tissue fluid is mixed especially in the blood sampling method, blood was collected by the double syringe method or the indwelling needle installation method in principle.
４．年令分布について
２０例の症例を４９才までと５０〜５９才、６０才以上に分けて年令分布をみると、次の如くであった。
年令 症例 平均年令
２７〜４９ ８（１） ３７．５
５０〜５９ ６（３） ５４．５
６０〜７１ ６（４） ６４．８
（ ）内は女性
男性１２名 ２７才より６５才 平均年令 ４５．１才
女性 ８名 ４６才より７１才 平均年令 ５９．４才
全平均年令 ５０．８才
4). About age distribution The distribution of age was divided into 20 cases up to 49 years old, 50-59 years old and over 60 years old.
Age Case Average age 27-49 8 (1) 37.5
50-59 6 (3) 54.5
60-71 6 (4) 64.8
Figures in parentheses are: 12 female men, 65 years old from 27 years old, 45.1 years old, female 8 persons 71 years old, from 46 years old Average age: 59.4 years old
Overall average age 50.8
Ｃ．症例の要因分析
ドック入院の症例であるので、健康状態に関して疾病の有無と日常生活上の注意事項、要精密検査、要治療の判定がされた。最近のドック検査は生活習慣病に重点がおかれているので、これに準拠し、要因として体重・脂質・血糖値・動脈硬化性病変の有無と肝機能障害に重点をおき症例を検討した。
上記の各要因に対し、表３の如く点数を按分し、健康状態により正常例（Ａ群）、他疾患例（Ｂ群）と生活習慣病或はその多数要因例（Ｃ群）の３群に分け、Ａ・Ｂ・Ｃ群の各要因に対する配点を施行すると、表６、７、８の如き結果となった。
更に通常の寝具及び寝衣を使用した対照群をＫ群、本発明の寝具及び寝衣使用群をＰＬ群とした。
C. Factor analysis of the case Because the patient was hospitalized at the dock, the health status was checked for the presence of illness, precautions for daily life, close examination, and treatment required. The recent dock tests focused on lifestyle-related diseases. Based on this, we examined cases with emphasis on factors such as weight, lipids, blood glucose levels, the presence or absence of arteriosclerotic lesions, and liver dysfunction.
For each of the above factors, the scores are apportioned as shown in Table 3, and three groups of normal cases (Group A), other disease cases (Group B), and lifestyle-related diseases or their multiple factors (Group C) depending on their health status The results shown in Tables 6, 7, and 8 were obtained when the points were assigned to each of the factors A, B, and C.
Furthermore, a control group using normal bedding and nightclothes was designated as group K, and a bedding and nightclothes use group of the present invention was designated as PL group.
4. その他
(1) 動脈硬化（A）に由来するもの…点数1
高血圧症、冠動脈硬化症、治療中のもの
既往に狭心症、心筋梗塞、脳梗塞のあるもの
(2) 肝機能障害（H）
1. GOT、GPT、γ−GPT値 100以下 1点
2. GOT、GPT、γ−GPT値 100以上 2点
3. LDH、LAP、ALP値上昇 1点
1+3の合併 2点
4. Other
(1) Derived from arteriosclerosis (A): 1 point
Hypertension, coronary sclerosis, history of treatment, angina pectoris, myocardial infarction, cerebral infarction
(2) Liver dysfunction (H)
1. GOT, GPT, γ-GPT value 100 or less 1 point
2. GOT, GPT, γ-GPT value 100 or more 2 points
3. LDH, LAP, ALP value increase 1 point
1 + 3 merger 2 points
Ｋ群（通常の寝具及び寝衣使用）とＰＬ群（本発明の寝具及び寝衣使用）について、夫々寝具及び寝衣使用前後に採血した。尚午睡前検査を前、午睡後検査を後として表現し検討した。
これらの検査結果の中から、血液粘度、血漿粘度及び血液中の硝酸イオンの濃度の検査結果を示す。
Blood was collected before and after the use of the bedding and the nightclothes in the K group (use of normal bedding and nightclothes) and the PL group (use of the bedding and nightclothes of the present invention), respectively. The examination before the nap was expressed as before and the examination after nap was expressed as after.
Among these test results, the test results of blood viscosity, plasma viscosity, and nitrate ion concentration in blood are shown.
表９の結果から、本発明の組成物を用いた寝具および寝衣を使用すると、血液中の硝酸イオンの濃度が高くなることがわかった。したがって、体内でＮＯが発生しているものと考えられる。 From the results in Table 9, it was found that the concentration of nitrate ions in the blood increased when the bedding and nightclothes using the composition of the present invention were used. Therefore, it is considered that NO is generated in the body.
Claims (9)
（工程２）前記工程１で得られた混合物を８００〜１０００℃で加熱する加熱工程とを有する、
請求項１〜５の焼成体の製造方法。 (Step 1) a mixing step of mixing components (i) to (v) and optionally component (vi) to obtain a mixture;
(Step 2) A heating step of heating the mixture obtained in Step 1 at 800 to 1000 ° C.,
The manufacturing method of the sintered body of Claims 1-5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018061842A JP6606213B2 (en) | 2018-03-28 | 2018-03-28 | Health promoting composition that generates photons and ions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018061842A JP6606213B2 (en) | 2018-03-28 | 2018-03-28 | Health promoting composition that generates photons and ions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019173207A JP2019173207A (en) | 2019-10-10 |
| JP6606213B2 true JP6606213B2 (en) | 2019-11-13 |
Family
ID=68166504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018061842A Active JP6606213B2 (en) | 2018-03-28 | 2018-03-28 | Health promoting composition that generates photons and ions |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6606213B2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7362955B1 (en) * | 2023-03-15 | 2023-10-17 | 俊夫 小室 | fired body |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5242870B2 (en) * | 2001-09-11 | 2013-07-24 | 帝人化成株式会社 | Flame retardant resin composition |
| PL207023B1 (en) * | 2002-03-29 | 2010-10-29 | Ngk Insulators Ltd | Silicon carbide based porous material and method for production thereof |
| AU2003242081B2 (en) * | 2002-06-05 | 2006-04-27 | Toshio Komuro | Antithrombogenic platiniferous ceramic composition and article containing the same |
| JP4657621B2 (en) * | 2003-06-10 | 2011-03-23 | 昭和電工株式会社 | Perovskite-type titanium-containing composite oxide particles, production method and use thereof |
| JPWO2005044447A1 (en) * | 2003-11-06 | 2007-05-17 | 東亞合成株式会社 | Composite oxidation type titania photocatalyst and use thereof |
| NZ547071A (en) * | 2003-12-19 | 2010-05-28 | Celanese Int Corp | Preparation of palladium / gold catalyst on a support when prepared from halide free precursors |
| ES2371007T3 (en) * | 2003-12-19 | 2011-12-26 | Celanese International Corporation | CATALYSTS CONTAINING RHODIUM. |
| WO2005108327A1 (en) * | 2004-05-06 | 2005-11-17 | Asahi Glass Company, Limited | Method for producing multilayer dielectric body |
| EP2159233A1 (en) * | 2005-05-30 | 2010-03-03 | Basf Se | Process for the colouring of polymer compositions comprising polyolefins. |
| JP4658813B2 (en) * | 2006-01-16 | 2011-03-23 | 出光テクノファイン株式会社 | Antibacterial fibers, woven or knitted fabrics, non-woven fabrics, wallpaper, and insulation |
| JP2008308644A (en) * | 2007-06-18 | 2008-12-25 | Teijin Fibers Ltd | Flame-retardant copolyester composition and flame-retardant polyester fiber |
| WO2009125847A1 (en) * | 2008-04-11 | 2009-10-15 | 株式会社エルブ | Noble-metal-supporting inorganic material, process for producing the same, food additive, and process for producing food |
| US8604252B2 (en) * | 2009-07-02 | 2013-12-10 | Basf Se | Supported noble metal comprising catalyst for oxidative dehydrogenation or epoxidation |
| JP5582150B2 (en) * | 2010-02-10 | 2014-09-03 | 株式会社村田製作所 | Ceramic sintered body and method for producing the same |
| JP2013128569A (en) * | 2011-12-20 | 2013-07-04 | Erubu:Kk | Freshness keeping device |
| JP6182714B2 (en) * | 2012-11-29 | 2017-08-23 | 株式会社エルブ | COMPOSITE CERAMIC MATERIAL AND ITS MANUFACTURING METHOD, COOKER FOR COOKER, MATTRESS, AND FIBER |
| JP6727022B2 (en) * | 2015-04-27 | 2020-07-22 | ダイワボウホールディングス株式会社 | Regenerated cellulose fiber containing functional material, method for producing the same, and fiber structure containing the same |
| JP6786057B2 (en) * | 2016-04-14 | 2020-11-18 | 日本エクスラン工業株式会社 | Functional component Sustained release fiber, fiber structure having the fiber and underwear, and method for regenerating them |
-
2018
- 2018-03-28 JP JP2018061842A patent/JP6606213B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019173207A (en) | 2019-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008239606A (en) | Antithrombogenic platinum-containing ceramic composition and article containing the same | |
| JP4195562B2 (en) | Far-infrared radiation composition excellent in charge removal, and fiber and fiber product containing the same | |
| KR960000473B1 (en) | Slight infrared energy radiation powder & synthetic fiber and fiber containing articles the above mentioned | |
| JP2008045240A (en) | Functional fiber and method for producing the same, and textile product | |
| JP6606213B2 (en) | Health promoting composition that generates photons and ions | |
| JP6182714B2 (en) | COMPOSITE CERAMIC MATERIAL AND ITS MANUFACTURING METHOD, COOKER FOR COOKER, MATTRESS, AND FIBER | |
| CN1437664A (en) | Laminated filament | |
| JP2011241522A (en) | Fiber and fiber containing mineral radiating application products terahertz wave | |
| EP1316637B1 (en) | Healthy fiber products | |
| CN107984856A (en) | A kind of Double-face fabric cool in summer and warm in winter and its preparation process | |
| JP7362955B1 (en) | fired body | |
| JP4067547B2 (en) | Functional fiber, functional yarn and fabric material | |
| KR20150001506A (en) | Preparation method of planar heating sheet with improved emission property of far-infrared radiation and negative ions, and planar heating sheet prepared by the same | |
| JP2637054B2 (en) | Liquid phase far-infrared radiation composition and method for producing the same | |
| JP3797170B2 (en) | Acrylic synthetic fibers and fiber composites thereof | |
| KR930008252B1 (en) | Preparation of polypropylene filament non-woven fabric having superior antibacterial deodorant and infrared ray radial property | |
| JP2879024B2 (en) | A method for producing rayon having far-infrared radiation properties, antibacterial properties, deodorizing properties, fungicidal properties and insect repellency, and having an antistatic effect | |
| JP2003010019A (en) | Quilt | |
| JP2010121252A (en) | Knitted and woven fabric for far infrared radiation clothes and footgear | |
| TWM279262U (en) | Anti-mite bedding appliance | |
| JP2000070095A (en) | Thick bedquilt | |
| JPH0234115A (en) | Bedquilt having high warmth retaining property | |
| JPH03193970A (en) | Fiber having heat retaining property and electrostatic property or product thereof | |
| JPH07185020A (en) | Aerosol spraying agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181121 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20181121 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20190108 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190305 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190402 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190424 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190702 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191008 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191017 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6606213 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |